Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis

Dear Editor Based on the erratum published in February 2019 issue of the European Journal of Endocrinology by Esposito et al. (1), we have decided to update the meta-analyses of our systematic review published last year (2), in which the above-mentioned study was included. The corrected data have not changed our conclusions (Fig. 1). We reaffirm that in comparison with studies published before 2008, standardized mortality rate (SMR) in acromegaly decreased in the last decade, probably due to the most frequent use of somatostatin analogs as adjuvant therapy in patients not controlled with surgery (SMR before 2008: 1.76, 95% CI: 1.52–2.04; SMR after 2008: 1.35, 95% CI: 0.99–1.85 and SMR: 1.26, 95% CI: 1.03–1.54, respectively, original and updated meta-analysis). All revised analysis and figures are available on request. Cesar Boguszewski is an Associate Editor of European Journal of Endocrinology. Cesar Boguszewski was not involved in the review or editorial process for this paper, on which he is listed as an author. The other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this article.